pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Carospir
drug
save

spironolactone

Marketedupdated 3mo ago
by CMP Pharma Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 6
  • drugALDACTONE85 co-mentions · 43 sources
  • tagApproval84 co-mentions · 42 sources
  • tagSmall Molecule42 co-mentions · 42 sources
  • companySun Pharmaceutical Industries Ltd2 co-mentions · 1 sources
  • companyFrontida Biopharm Inc1 co-mentions · 1 sources
  • tagRecall1 co-mentions · 1 sources

indications

investigational
Hypertension

all catalysts(0)

nothing on the calendar yet

Trials studying spironolactone

  • phase2Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)recruitingn=100
  • phase2A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progressionnot yet recruitingn=68
  • phase3Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactonecompletedn=24
  • phase3A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Diseaserecruitingn=30
  • phase3A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjectscompletedn=24
  • phase3Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjectscompletedn=24
  • phase4Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosingrecruitingn=20
  • phase4Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactonecompletedn=366
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 28, 2036
~10.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

  • Oct 28, 2036formulationUS 10493083
  • Oct 28, 2036formulationUS 10624906
  • Oct 28, 2036formulationUS 10660907
  • Oct 28, 2036formulationUS 10888570
  • Oct 28, 2036formulationUS 11389461
  • Oct 28, 2036method-of-use (U-3402)US 11395828
  • Oct 28, 2036formulationUS 11491166
  • Oct 28, 2036formulationUS 9757394

News(0)

no news has mentioned this drug yet

brand
Carospir
generic
spironolactone [INN]
indication
Congestive Heart Failure (Heart Failure)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?